Background: There are a number of complementary and alternative therapies for the primary dysmenorrhea (PD) and their efficacy has been assessed by several systematic reviews. But only pair-wised drugs have been evaluated in the traditional meta-analyses and conflicting interpretation of results also existed among different studies. Here, a protocol for a network meta-analysis will be presented aimed to compare the efficacy and safety of different complementary and alternative therapies for PD. Methods: All randomized controlled trials of complementary and alternative therapies for the PD will be included. The primary outcomes of our interest are pain intensity and pain duration and the secondary outcomes are quality of life, clinical effective rate, and adverse events. We will search relevant database, the ongoing trial, previous relevant reviews and reference lists, and so on. The identification and selection of studies and data extraction will be conducted by two independent reviewers. We will perform a battery of pairwise meta-analyses and Bayesian network meta-analyses to assess the relative outcomes of different complementary and alternative therapies. We will use the surface under the cumulative ranking curve values and the mean ranks to get the treatment hierarchy, and then use the node-splitting method to evaluate consistency. The softwares WinBUGS 1.4.3 and STATA will be selected and the quality of the evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation instrument. Ethics and dissemination: This review does not require ethical approval. PROSPERO registration number: PROSPERO CRD42018107763.

IntroductionAchieving efficacious and safe treatments for unstable angina pectoris (UAP) is still a challenging clinical problem. The availability of different oral Chinese patent medicines frequently poses a practical challenge to clinicians, namely, which one to choose as first-line regimen for treatment. This study aims to examine the comparative effectiveness and safety of oral Chinese patent medicines for UAP on the national essential drugs list of China.Methods and analysisWe will conduct a network meta-analysis (NMA) of all randomised controlled trials to evaluate the use of oral Chinese patent medicines as adjuvant for the treatment of UAP. We will explore eight electronic databases from their inception to June 2018 and search for grey literature. Primary outcomes include mortality and the cardiovascular events. Secondary outcomes include: (1) symptom improvement; (2) ECG improvement; (3) frequency of acute angina attack; (4) duration of angina; (5) adverse effects. Two independent authors will screen titles and abstracts, review full texts, extract data, assess the risk of bias using the Cochrane risk of bias tool and assess the quality of evidence and strength of the recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE). If adequate data are available, NMA will be performed with Bayesian analysis methods.Ethics and disseminationThe NMA will help us to reduce the uncertainty of interventions and help clinicians to make optimal and more accurate therapeutic decisions for adults with UAP. Therefore, we will publish the findings of this study in a peer-reviewed journal. No ethics approval is necessary for this study based on the nature of its design.Trial registration numberCRD42018092822.

Background: Endometriosis is a common disease of women of childbearing age. In recent years, the incidence of endometriosis has been on the rise. The main clinical manifestations are pelvic pain and infertility. In recent years, traditional Chinese patent medicine (TCMP) has played an important role in the treatment of endometriosis. So far, there is a lack of comparison among all the current common TCPMs for endometriosis. Consequently, it is indispensable to propose a network meta-analysis (NMA) protocol to discuss the strengths and weaknesses of different TCMPs. Methods: We will comprehensively and systematically retrieve the relevant Chinese and English databases from their inceptions to the May 2019. All randomized controlled trials (RCTs) of TCMPs for Endometriosis will be included. Two researchers will independently screen literature, extract data and assess the risk of bias of included studies. We will conduct pairwise meta-analyses and Bayesian network meta-analyses to assess all the available evidence. Data will be analyzed using STATA and WinBUGS software. Results: This work will compare and rank the relative efficacy of different TCPMs in the treatment of endometriosis in detail. Conclusion: The results of this study will provide reliable evidence for the selection of clinical treatment program and guideline development. PROSPERO registration number: CRD42019127781.

Background: As a common symptom of perimenopausal period, perimenopausal insomnia brings great pain to many women and families. Acupuncture has been accepted by people as the incidence rate of this disease increases. The purpose of this study is to systematically compare the safety and efficacy of various acupuncture treatments for perimenopausal insomnia through network meta-analysis. Methods: We will search Web of Science, PubMed, The Cochrane Library, Embase, Chinese National Knowledge Infrastructure (CNKI), Wan Fang Date, VIP database, conference papers and grey literature. All relevant Randomized controlled trial (RCT) using acupuncture for perimenopausal insomnia will be included. Two reviewers will independently search and screen date. Network meta-analysis will be completed by Stata and WinBUGS software. Results: This study will compare the efficacy and safety of different acupuncture treatments for perimenopausal insomnia. Conclusion: The result of this study will provide reliable evidence for evaluating the efficacy and safety of acupuncture in the treatment of perimenpausal insomnia. INPLASY registration number: INPLASY2020110047.